The Terminally Ill Need More Than the ‘Right to Try’ Two hundred cancer drugs are in Phase III trials. Congress can put them into patients’ hands today.

Dr. Marangos is author of 252 peer-reviewed research papers on neurobiology, and 4 books – three by Academic Press (the Neurobiological Research series of volumes) and a fourth titled “Emerging Strategies in Neuroprotection”. He is a founding editor of “The Journal of Molecular Neuroscience” and inventor on 14 issued patents. He spent 13 years at the NIMH and was adjunct professor of neurochemistry at GW School of Medicine during that time. He is co-Founder of five Biotech firms with over 20 years of experience as CEO of both public and private life science companies. He has had extensive experience in all aspects of the pharmaceutical and biotechnology industries from bench to product. This coupled with his academic experience has provided a global perspective on the entire medical R&D enterprise, in particular its faults, and remedies to speed the quest for cures.

https://www.wsj.com/articles/the-terminally-ill-need-more-than-the-right-to-try-1534200199?mod=searchresults&page=1&pos=1

https://www.prnewswire.com/news-releases/biomedica-partners-proposes-the-terminal-disease-act-300609691.html?tc=eml_cleartime

http://thehill.com/opinion/healthcare/383484-right-to-try-efforts-have-have-been-timid-and-poorly-conceived

https://www.prnewswire.com/news-releases/biomedica-partners-presents-major-reforms-in-terminal-disease-drug-development-at-magis-clinical-research-conference-300642731.html